moxifloxacin has been researched along with pemetrexed in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (pemetrexed) | Trials (pemetrexed) | Recent Studies (post-2010) (pemetrexed) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,469 | 657 | 1,695 |
| Protein | Taxonomy | moxifloxacin (IC50) | pemetrexed (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.1 | |
| Dihydrofolate reductase | Homo sapiens (human) | 4.0309 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 2.3 | |
| Thymidylate synthase | Homo sapiens (human) | 8.1787 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 2.3 | |
| Folate receptor beta | Homo sapiens (human) | 0.2585 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2417 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.0342 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.07 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0928 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.655 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.0229 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and pemetrexed
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |